Blockade of voltage-gated sodium channels inhibits invasion of endocrine-resistant breast cancer cells

International Journal of Oncology

Volumn 48, Issue 1, 2016, Pages 73-83

  Mohammed, Fatima H ^a   Khajah, Maitham A ^a   Yang, Ming ^b   Brackenbury, William J ^b   Luqmani, Yunus A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Breast cancer; Endocrine resistance; Invasion; Matrix metalloproteinase; Nav1.5; Phenytoin; Tetrodotoxin; Voltage gated Na+ channels

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AGAROSE; CATHEPSIN E; ESTROGEN RECEPTOR; KALLIKREIN; MATRIGEL; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENYTOIN; PROTEIN KINASE B; PROTEINASE; PROTEOME; SMALL INTERFERING RNA; TETRODOTOXIN; VOLTAGE GATED SODIUM CHANNEL; ESTROGEN RECEPTOR ALPHA; SCN5A PROTEIN, HUMAN; SODIUM CHANNEL NAV1.5;

ARTICLE; ASSAY; BREAST CANCER CELL LINE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; IMMUNOFLUORESCENCE; INHIBITION KINETICS; ION CURRENT; MTT ASSAY; PRIORITY JOURNAL; TUMOR INVASION; WESTERN BLOTTING; WHOLE CELL PATCH CLAMP; WOUND HEALING ASSAY; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF-7 CELL LINE; PATCH CLAMP TECHNIQUE; PATHOLOGY;

BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; NEOPLASM INVASIVENESS; PATCH-CLAMP TECHNIQUES; PHENYTOIN; TETRODOTOXIN;

EID: 84953281211     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3239     Document Type: Article

References (59)

1. Y ang LH, Tseng HS, Lin C, Chen LS, Chen ST, Kuo SJ and Chen DR: Survival benefit of tamoxifen in estrogen receptornegative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer 15: 288-295, 2012.
2. Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 38: 1197-1217, 2011.
3. Y ang M, Kozminski DJ, Wold LA, Modak R, Calhoun JD, Isom LL and Brackenbury WJ: Therapeutic potential for phenytoin: Targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res Treat 134: 603-615, 2012.
4. Onkal R and Djamgoz MBA: Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: Clinical potential of neonatal Nav1.5 in breast cancer. Eur J Pharmacol 625: 206-219, 2009.
5. Chioni A-M, Brackenbury WJ, Calhoun JD, Isom LL and Djamgoz MB: A novel adhesion molecule in human breast cancer cells: Voltage-gated Na+ channel beta1 subunit. Int J Biochem Cell Biol 41: 1216-1227, 2009.
6. Brackenbury WJ, Djamgoz MBA and Isom LL: An emerging role for voltage-gated Na+ channels in cellular migration: Regulation of central nervous system development and potentiation of invasive cancers. Neuroscientist 14: 571-583, 2008.
7. Brackenbury WJ, Davis TH, Chen C, Slat EA, Detrow MJ, Dickendesher TL, Ranscht B and Isom LL: Voltage-gated Na+ channel beta1 subunit-mediated neurite outgrowth requires Fyn kinase and contributes to postnatal CNS development in vivo. J Neurosci 28: 3246-3256, 2008.
8. Gillet L, Roger S, Bougnoux P, Le Guennec J-Y and Besson P: Beneficial effects of omega-3 long-chain fatty acids in breast cancer and cardiovascular diseases: Voltage-gated sodium channels as a common feature? Biochimie 93: 4-6, 2011.
9. Hernández-Plata E: Role of the voltage-gated sodium channels in the metastatic capacity of cancer cells. Rev Invest Clin 64: 567-575, 2012 (In Spanish).
10. Brackenbury WJ and Isom LL: Voltage-gated Na channels: Potential for subunits as therapeutic targets. Expert Opin Ther Targets 12: 1191-1203, 2008.
11. Roger S, Potier M, Vandier C, Besson P and Le Guennec J-Y: Voltage-gated sodium channels: New targets in cancer therapy? Curr Pharm Des 12: 3681-3695, 2006.
12. Potier M, Joulin V, Roger S, Besson P, Jourdan ML, Leguennec JY, Bougnoux P and Vandier C: Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther 5: 2946-2953, 2006.
13. Goldin AL: Resurgence of sodium channel research. Annu Rev Physiol 63: 871-894, 2001.
14. Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC, Kallen RG, Mandel G, Meisler MH, Netter YB, et al: Nomenclature of voltage-gated sodium channels. Neuron 28: 365-368, 2000.
15. Hernández-Plata E, Ortiz CS, Marquina-Castillo B, Medina-Martinez I, Alfaro A, Berumen J, Rivera M and Gomora JC: Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer. Int J Cancer 130: 2013-2023, 2012.
16. Yildirim S, Altun S, Gumushan H, Patel A and Djamgoz MBA: Voltage-gated sodium channel activity promotes prostate cancer metastasis in vivo. Cancer Lett 323: 58-61, 2012.
17. Isom LL and Catterall WA: Na+ channel subunits and Ig domains. Nature 383: 307-308, 1996.
18. Diss JK, Archer SN, Hirano J, Fraser SP and Djamgoz MB: Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate 48: 165-178, 2001.
19. Djamgoz MB and Onkal R: Persistent current blockers of voltagegated sodium channels: A clinical opportunity for controlling metastatic disease. Recent Patents Anticancer Drug Discov 8: 66-84, 2013.
20. Laniado ME, Lalani EN, Fraser SP, Grimes JA, Bhangal G, Djamgoz MB and Abel PD: Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 150: 1213-1221, 1997.
21. Nelson M, Millican-Slater R, Forrest LC and Brackenbury WJ: The sodium channel 1 subunit mediates outgrowth of neuritelike processes on breast cancer cells and promotes tumour growth and metastasis. Int J Cancer 135: 2338-2351, 2014.
22. Fraser SP, Diss JKJ, Chioni A-M, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, et al: Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 11: 5381-5389, 2005.
23. Brisson L, Gillet L, Calaghan S, Besson P, Le Guennec JY, Roger S and Gore J: Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. Oncogene 30: 2070-2076, 2011.
24. Gillet L, Roger S, Besson P, Lecaille F, Gore J, Bougnoux P, Lalmanach G and Le Guennec JY: Voltage-gated sodium channel Activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells. J Biol Chem 284: 8680-8691, 2009.
25. L uqmani YA, Al Azmi A, Al Bader M, Abraham G and El Zawahri M: Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells. Int J Oncol 34: 231-242, 2009.
26. Khajah MA, Al Saleh S, Mathew PM and Luqmani YA: Differential effect of growth factors on invasion and proliferation of endocrine-resistant breast cancer cells. PLoS One 7: e41847, 2012.
27. Al Saleh S, Al Mulla F and Luqmani YA: Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS One 6: e20610, 2011.
28. Brackenbury WJ, Calhoun JD, Chen C, Miyazaki H, Nukina N, Oyama F, Ranscht B and Isom LL: Functional reciprocity between Na+ channel Nav1.6 and beta1 subunits in the coordinated regulation of excitability and neurite outgrowth. Proc Natl Acad Sci USA 107: 2283-2288, 2010.
29. Brackenbury WJ and Djamgoz MBA: Activity-dependent regulation of voltage-gated Na+ channel expression in Mat-LyLu rat prostate cancer cell line. J Physiol 573: 343-356, 2006.
30. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, Sarvazyan N, Irby R, Strausberg RL, Hales TG, et al: Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res 70: 6957-6967, 2010.
31. House CD, Wang BD, Ceniccola K, Williams R, Simaan M, Olender J, Patel V, Baptista-Hon DT, Annunziata CM, Gutkind JS, et al: Voltage-gated Na+ channel activity increases colon cancer transcriptional activity and invasion via persistent MAPK signaling. Sci Rep 5: 11541, 2015.
32. Carrithers MD, Chatterjee G, Carrithers LM, Offoha R, Iheagwara U, Rahner C, Graham M and Waxman SG: Regulation of podosome formation in macrophages by a splice variant of the sodium channel SCN8A. J Biol Chem 284: 8114-8126, 2009.
33. Brisson L, Driffort V, Benoist L, Poet M, Counillon L, Antelmi E, Rubino R, Besson P, Labbal F, Chevalier S, et al: NaV1.5 Na(+) channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia. J Cell Sci 126: 4835-4842, 2013.
34. Besson P, Driffort V, Bon É, Gradek F, Chevalier S and Roger S: How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells? Biochim Biophys Acta 1848: 2493-2501, 2015.
35. Brackenbury WJ: Voltage-gated sodium channels and metastatic disease. Channels (Austin) 6: 352-361, 2012.
36. Maness PF and Schachner M: Neural recognition molecules of the immunoglobulin superfamily: Signaling transducers of axon guidance and neuronal migration. Nat Neurosci 10: 19-26, 2007.
37. D ing Y, Brackenbury WJ, Onganer PU, Montano X, Porter LM, Bates LF and Djamgoz MB: Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity. J Cell Physiol 215: 77-81, 2008.
38. Mantegazza M, Curia G, Biagini G, Ragsdale DS and Avoli M: Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9: 413-424, 2010.
39. Hille B: Ionic channels of excitable membranes. Cell 69: 579, 1992.
40. Crill WE: Persistent sodium current in mammalian central neurons. Annu Rev Physiol 58: 349-362, 1996.
41. Ju YK, Saint DA and Gage PW: Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 497: 337-347, 1996.
42. Kunzelmann K: Ion channels and cancer. J Membr Biol 205: 159-173, 2005.
43. Turnbull DM, Rawlins MD, Weightman D and Chadwick DW: 'Therapeutic' serum concentration of phenytoin: The influence of seizure type. J Neurol Neurosurg Psychiatry 47: 231-234, 1984.
44. Nelson M, Yang M, Dowle AA, Thomas JR and Brackenbury WJ: The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Mol Cancer 14: 13, 2015.
45. Brackenbury WJ, Chioni A-M, Diss JKJ and Djamgoz MBA: The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 101: 149-160, 2007.
46. Zucker S, Cao J and Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19: 6642-6650, 2000.
47. Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27, 2011.
48. Sekton B: Matrix metalloproteinases-an overview. Rev Bras Ter Intensiva 23: 222-227, 2011.
49. Gao R, Wang J, Shen Y, Lei M and Wang Z: Functional expression of voltage-gated sodium channels Nav1.5 in human breast cancer cell line MDA-MB-231. J Huazhong Univ Sci Technolog Med Sci 29: 64-67, 2009.
50. Azuma T, Yamada M, Murakita H, Nishikawa Y, Kohli Y, Yamamoto K and Hori H: Cathepsin E expressed in pancreatic cancer. Adv Exp Med Biol 362: 363-366, 1995.
51. Azuma T, Hirai M, Ito S, Yamamoto K, Taggart RT, Matsuba T, Yasukawa K, Uno K, Hayakumo T and Nakajima M: Expression of cathepsin E in pancreas: A possible tumor marker for pancreas, a preliminary report. Int J Cancer 67: 492-497, 1996.
52. Kawakubo T, Yasukochi A, Toyama T, Takahashi S, Okamoto K, Tsukuba T, Nakamura S, Ozaki Y, Nishigaki K, Yamashita H, et al: Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer. Carcinogenesis 35: 714-726, 2014.
53. Hagen NA, Fisher KM, Lapointe B, du Souich P, Chary S, Moulin D, Sellers E and Ngoc AH; Canadian Tetrodotoxin Study Group: An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain. J Pain Symptom Manage 34: 171-182, 2007.
54. D ib-Hajj SD, Black JA and Waxman SG: Voltage-gated sodium channels: therapeutic targets for pain. Pain Med 10: 1260-1269, 2009.
55. Clare JJ : Targeting voltage-gated sodium channels for pain therapy. Expert Opin Investig Drugs 19: 45-62, 2010.
56. Busserolles J, Alloui A, Lazdunski M and Eschalier A: Use of riluzole to treat or prevent the adverse effects of antineoplastic agents. US Patent 2013/0064775 A1. Filed: March 2, 2011; issued March 14, 2013.
57. Yip D, Le MN, Chan JL K, Lee JH, Mehnert JA, Yudd A, Kempf J , Shih WJ, Chen S and Goydos JS: A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15: 3896-3902, 2009.
58. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI and Buggy DJ: Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: A retrospective analysis. Anesthesiology 109: 180-187, 2008.
59. Mao L, Lin S and Lin J: The effects of anesthetics on tumor progression. Int J Physiol Pathophysiol Pharmacol 5: 1-10, 2013.